Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022
(RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage --
SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively -- -- Favorable safety & reactogenicity profile comparable to sali...
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- -- Preliminary Phase I data in target older adult population is on track for H2-2024 -- SHANGHAI, ...
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses through at least 3-weeks-- --Durable efficacy and PK profile expected to support convenient dosing interval of ≥2-weeks, compared to daily or weekly d...
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage--
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
-- Clover's seasonal influenza vaccine BLA submission has been completed in
Brazil, boosting Clover's global presence --
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
